medicalxpress.com
A newly developed vaccine for respiratory syncytial virus (RSV) is set to provide vital protection for older adults, particularly those aged 75 and over. According to recent research from the University of Aberdeen and the MRC-University of Glasgow Center for Virus Research, the vaccine could prevent thousands of deaths annually and significantly reduce the healthcare burden caused by RSV-related respiratory infections. Despite this, experts warn that vaccine fatigue and hesitancy could limit its uptake among those who need it most.
What’s New?
The new vaccine has demonstrated impressive efficacy, reducing RSV-related lower respiratory tract infections by 86% in the first year post-vaccination. If at least 70% of the eligible population receives the vaccine, it could prevent up to 2,800 deaths annually and drastically cut down on GP consultations, hospitalizations, and intensive care admissions. This vaccine launch coincides with the growing recognition that RSV, often associated with infants, also poses significant health risks to the elderly. The UK’s new vaccination program targets adults aged 75 to 79, marking a critical step in addressing this public health challenge.
Why It Matters
RSV is a major cause of serious lung infections in older adults, contributing to an estimated 8,000 deaths and 175,000 GP visits each year in the UK alone. The pressures on healthcare systems, especially during the winter months, make this vaccine an essential tool in protecting vulnerable populations and easing the strain on the National Health Service (NHS). With influenza and COVID-19 vaccines already in use, adding the RSV vaccine offers a more comprehensive defense against respiratory illnesses for older adults. Public health officials emphasize the importance of overcoming vaccine hesitancy to maximize the vaccine's potential and protect the health of this at-risk group.